Legal updates and opinions
News / News
JSE efforts to reduce red tape in Section 9 of the Johannesburg Stock Exchange Listing Requirements: Part 2
Johannesburg Stock Exchange Listing
On 5 March 2021, the Issuer Regulation Division of the JSE issued a Market Notice on a JSE Consultation Paper titled “Cutting Red Tape Aimed at Effective and Appropriate Regulation: Request for Comments“. The call for comments closed on 9 April 2021, however, due to the vast interest received from stakeholders, the JSE allowed extensions on request from the public. Please see our initial points which we discussed previously.
Taking into account the comments received from market participants and stakeholders, the JSE has proposed amendments to the JSE Listings Requirements, which will now be subject to further public consultation processes pursuant to the provisions of the JSE Listings Requirements and the Financial Markets Act No 19 of 2012.
Section 9 of the JSE Listings Requirements
In respect of Section 9 of the JSE Listings Requirements, the proposed amendments include –
- increasing the existing 10% limitation to 30% when categorising a transaction which falls within the ordinary course of business of an issuer, measured against the market capitalisation of such an issuer at the time;
- increasing the factors to be considered by the JSE when assessing whether a transaction is in the ordinary course of business;
- a new provision excluding any transactions with directors and/or their associates from the ordinary course of business exemption; and
- a new provision in terms of which transactions classified as ordinary course of business be announced through SENS immediately after the terms have been agreed and where the categorisation is equal to 5% or more. The announcement must deal with the salient details of the ordinary course of business transaction (excluding pricing information as it may be commercially sensitive) and the corporate approvals obtained by the issuer to conclude the ordinary course of business transaction. The announcement must also include “an opinion from the independent members of the board of directors of the issuer that the transaction is in fact in the ordinary course of business and that the transaction was concluded on an arm’s length basis“. Without getting into a detailed exposition of this requirement, what this essentially means is that independent directors must be able to disclose pertinent insights and observations on the transaction in making such an opinion.
The JSE has invited comments to be sent directly to Alwyn Fouchee at AlwynF@jse.co.za on the proposed amendments to the JSE Listings Requirements by no later than 13 September 2021.
Read part of one of the JSE efforts to reduce red tape in Section 9 of the Johannesburg Stock Exchange Listing Requirements.
By Elliott Wood, Director and Bafana Ntuli, Director
Latest News
When silence becomes complicity: Constructive dismissal, workplace bullying and the cost of doing nothing
by Bradley Workman-Davies, Director Constructive dismissal remains one of the more difficult claims to prove in South African labour law. [...]
Nxele v Chairperson of the Disciplinary Hearing: Mudau NO and others, [2026] 6 BLLR 628 (LC): Clarifying the operation of section 188A(11) of the Labour Relations Act 66 of 1995
by Bankey Sono, Director and Sandile Mogweng, Candidate Attorney The Labour Court in Nxele v Chairperson of the Disciplinary Hearing: [...]
No grout about it: The LAC cements section 197 principles
by Bradley Workman-Davies, Director Section 197 of the Labour Relations Act has long been one of the most misunderstood and [...]
Making sense of death: A brief overview of inquest proceedings
by Dakalo Singo, Director and Head of Pro Bono By its very nature, death is tragic. The death of a [...]
Is cryptocurrency ‘capital’? Taking the Mangundhla judgment under the loop
by Deon Griessel, Director 1. Introduction Two Gauteng Division judgements have reached diametrically opposite conclusions on the question as to [...]
Agonists and APIs: High Court Injects Clarity into Compounding Debate
by Neil Kirby, Director and Head of Healthcare & Life Sciences and Slade van Rooyen, Associate The practice of compounding [...]
